Biorasi
Biorasi is a global, award-winning, full-service contract research organization (CRO) that delivers faster clinical trials for small and midsized pharmaceutical and device companies, offering a wide range of specialized services and solutions.
Services
Biorasi offers a wide range of clinical research solutions tailored to the needs of small and midsized pharmaceutical and device companies. Their services include conducting Phase Ib-III Trials, Safety and Pharmacovigilance Solutions, and Decentralized and Virtual Solutions. Additionally, they provide specialized patient engagement and recruitment strategies designed to accelerate patient identification, engagement, and enrollment processes.
Specialized Therapeutic Areas
Biorasi has extensive experience in several therapeutic areas, including Neurology, Cell & Gene Therapy, Dermatology, Oncology, Nephrology, Pulmonology, and Hematology. Their expertise is backed by dedicated centers such as the Neurology Center of Excellence and the Rare Disease Center of Excellence, which focus on innovative solutions for complex clinical trials.
Neurology Center of Excellence
The Neurology Center of Excellence at Biorasi specializes in providing advanced clinical research solutions for a variety of neurological conditions. These include neurodegenerative diseases, neurodevelopmental disorders, psychiatric conditions, and movement disorders. This center leverages cutting-edge technology and industry expertise to deliver faster and more effective clinical trials.
Rare Disease Center of Excellence
Biorasi's Rare Disease Center of Excellence is dedicated to overcoming the unique challenges presented by rare disease clinical trials. This center utilizes advanced technology and a wealth of industry experience to ensure the successful execution of clinical studies in this specialized area. The goal is to address the specific needs of rare disease trials and deliver reliable results.
Global Reach and Patient Access
Biorasi operates on a global scale, with access to patient populations in over 100 countries. This extensive reach allows for more diverse and comprehensive clinical trials. Their decentralized and virtual solutions facilitate clinical trial conduct in remote or inaccessible locations, ensuring studies continue smoothly even during challenging conditions such as lockdowns.